Patents Examined by Shanon A. Foley
-
Patent number: 11883480Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.Type: GrantFiled: July 26, 2022Date of Patent: January 30, 2024Assignee: Merck Sharp & Dohme LLCInventors: Michael S. Ryan, Sherrie-Ann P. Martin, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
-
Patent number: 11878998Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: GrantFiled: November 11, 2021Date of Patent: January 23, 2024Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Patent number: 11879893Abstract: The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.Type: GrantFiled: August 9, 2022Date of Patent: January 23, 2024Assignee: NLC Pharma LtdInventor: Dorit Arad
-
Patent number: 11872280Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: May 31, 2022Date of Patent: January 16, 2024Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
-
Patent number: 11865083Abstract: The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.Type: GrantFiled: February 26, 2021Date of Patent: January 9, 2024Assignee: NATIONAL UNIVERSITY OF SINGAPOREInventors: Eng Eong Ooi, Kenneth Goh, Swee Sen Kwek, Choon Kit Tang
-
Patent number: 11865171Abstract: Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 ?g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.Type: GrantFiled: February 19, 2021Date of Patent: January 9, 2024Assignees: Zoetis Services LLC, United States of America, as represented by the Secretary of AgricultureInventors: Paul Joseph Dominowski, John Morgan Hardham, James Alan Jackson, Cyril Gerard Gay, Luis Leandro Rodriguez, Peter William Krug, Aida Elizabeth Rieder
-
Patent number: 11857585Abstract: A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.Type: GrantFiled: December 28, 2018Date of Patent: January 2, 2024Assignee: BIONOXX INC.Inventors: Taeho Hwang, Mong Cho
-
Patent number: 11857617Abstract: In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection by administration of an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of “vaccine breakthrough infections” after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection.Type: GrantFiled: November 12, 2021Date of Patent: January 2, 2024Assignee: TOPELIA AUST LIMITED (652 771 670)Inventor: Thomas Julius Borody
-
Patent number: 11858963Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.Type: GrantFiled: March 29, 2021Date of Patent: January 2, 2024Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
-
Patent number: 11851698Abstract: The present invention relates to a method for detecting a pathogen in cellular lysate by measuring pathogen-specific enzyme activity. The method comprises contacting the cellular lysate with a substrate the pathogen of interest recognizes and modifies, and obtaining a measurable, recordable, signal. The method may comprise detection of SARS-CoV viruses using the activity of SARS PLpro enzyme in tongue scrape lysate as a readout.Type: GrantFiled: February 5, 2023Date of Patent: December 26, 2023Assignee: MESA PHOTONICS, LLCInventors: Frauke Henrike Rininsland, Daniel James Kane
-
Patent number: 11845962Abstract: Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (1) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.Type: GrantFiled: March 28, 2019Date of Patent: December 19, 2023Assignee: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.Inventors: Yi Hong, Ting Yan, Jiangguo Ying, Haojie Zhang, Luyi Zhang, Li Zhang
-
Patent number: 11844831Abstract: The present invention describes immunogenic compositions containing immunogenic polypeptides of African Swine Fever (ASF) virus, including immunogenic compositions containing antigens other than ASF viral antigens, including antigens that may be used in immunization against pathogens that cause diarrheal diseases. Methods of eliciting an immune response with the immunogenic compositions as disclosed and methods of treating an ASF infection are also described.Type: GrantFiled: December 21, 2021Date of Patent: December 19, 2023Assignee: VST LLCInventor: Alan Young
-
Patent number: 11839642Abstract: Carrier compositions, including human-safe phages, equipped with one or more angiogenin-binding peptides, and optionally with tumor-homing peptides for use in anti-tumor therapies, are described. The angiogenin-binding peptides bind to and inactivate angiogenin molecules thereby blocking their angiogenic activity thus inhibiting angiogenesis in the tissue in which the compositions are localized.Type: GrantFiled: April 9, 2019Date of Patent: December 12, 2023Assignee: The Board of Regents of the University of OklahomaInventors: Chuanbin Mao, Yan Li
-
Patent number: 11835521Abstract: One aspect of the present invention is directed to a method for detecting acute Borna Disease Virus (BDV) infections. According to the invention, the presence of heterodimers of p24 BDV phosphoprotein and p40 BDV nucleoprotein in a sample is determined by means of antibodies of both proteins using a sandwich ELISA. The invention also relates to a diagnostic kit for a sandwich ELISA for detecting mute BDV infections. Said kit uses a antibody of p24 BDV phosphoprotein and a second primary antibody of p40 BDV nucleoprotein, at least one reporter-molecule-labelled secondary antibody, means for immobilising a primary antibody on a surface, and instructions for carrying out the method according to the invention. The invention also relates to the combination of the method according to the invention and the new diagnostic kit with known methods for detecting circulating immune complexes (CIC) and antibodies.Type: GrantFiled: September 11, 2018Date of Patent: December 5, 2023Inventors: Hanns Ludwig, Liv Bode
-
Patent number: 11833198Abstract: Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.Type: GrantFiled: March 15, 2018Date of Patent: December 5, 2023Assignee: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Ming Tan, Xi Jason Jiang
-
Patent number: 11827694Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: GrantFiled: February 22, 2023Date of Patent: November 28, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt Swanson, Philip R. Dormitzer
-
Patent number: 11826425Abstract: Enteroviruses, such as EV-A71, have been found to utilize hWARS as a cell surface receptor, with expression ofhWARS rendering cells susceptible to enteroviral infection. Reduction in hWARS cell surface activity reduces susceptibility to enteroviral infection and provides a mode for treatment or prevention of enteroviral infection and its sequelae. Similarly, expression of hWARS in cultured cells and animal models provides models for understanding enteroviral disease mechanisms and the development of vaccines and/or pharmaceuticals for preventing or treating enteroviral disease.Type: GrantFiled: September 13, 2017Date of Patent: November 28, 2023Assignee: VERSITECH LIMITEDInventors: Philip Man Lung Yeung, Fuk Woo Jasper Chan, Manson Fok, Johnson Yiu-Nam Lau, Kwok-Yung Yuen
-
Patent number: 11820812Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.Type: GrantFiled: December 29, 2021Date of Patent: November 21, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Kurt Swanson, Philip R. Dormitzer
-
Patent number: 11813320Abstract: Genetically engineered Foot and Mouth Disease Virus (FMDV) and related engineered proteins and polynucleotides, nanolipoprotein particles, compositions, methods and systems are described. The genetically engineered FMDV is modified by the strategic insertion of a protein tag into select regions of the FMDV genome which encode viral proteins that are exposed on the surface of the FMDV viral capsid. The inserted protein tag is displayed as a decoration or attachment on the viral capsid surface.Type: GrantFiled: February 16, 2021Date of Patent: November 14, 2023Assignees: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF AGRICULTURE, THE UNIVERSITY OF CONNECTICUTInventors: Aida E. Rieder, Teresa B. De Los Santos, Luis L. Rodriguez, Devendra Rai, Fayna C. Diaz-San Segundo, Paul D. Hoeprich
-
Patent number: 11813322Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to stabilized liquid immunogenic compositions and vaccines having a live attenuated viral antigen, and methods of using the same. The live attenuated viral antigen can be a live peste des petits ruminants (PPR) virus.Type: GrantFiled: June 5, 2020Date of Patent: November 14, 2023Inventors: Noel Yves Henri Jean Genin, David Pierre Corneille, Bradley Eddy